| Titan Pharmaceuticals is a pharmaceutical company developing therapeutics utilizing its drug delivery platform, ProNeura, for the treatment of select chronic diseases. Probuphine is a product based on its ProNeura technology approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder (OUD). Co. is conducting non-clinical studies with a nalmefene implant for the potential treatment of OUD under a grant from the National Institutes of Health. Co. is collaborating with the Walter Reed Army Institute of Research and South West Research Institute in the early non-clinical evaluation of the ProNeura platform in malaria prophylaxis. We show 26 historical shares outstanding datapoints in our TTNP shares outstanding history coverage, used to compute TTNP market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TTNP market cap history over the course of time is important for investors
interested in comparing TTNP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TTNP versus a peer is one thing; comparing
TTNP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TTNP can fluctuate over the course of history.
With this page we aim to empower investors researching TTNP by allowing them to research the TTNP market cap history.